https://www.selleckchem.com/pr....oducts/TSU-68(SU6668
Taken together, these data indicate in the context of ongoing phase 3 trial programs that patients with schizophrenia may soon have access to the first non-D2 blocking medication, which could drastically change the treatment landscape and improve outcomes for many of the individuals with schizophrenia who do not fully respond to or cannot tolerate currently available antipsychotic agents that currently all act via postsynaptic dopamine D2 receptor blockade.Importance Autoimmune encephalitis (AE) refers to a group of neuropsychiat
Like
Comment
Share
